The team behind Mindset

Our team of drug development experts and mental health experts are advancing psychedelic medicine through the introduction of optimized next generation therapies. With substantial experience in medicinal chemistry and behavioural pharmacology as well as a proven ability to drive growth in emerging sectors, we have the capabilities necessary to create novel approaches to treating mental health.


James Lanthier

Placeholder Img

Arvin Ramos


Joseph Araujo

CSO, Director

Malik Slassi, Ph.D.

Senior VP of Innovation

Jason Atkinson

Corporate Development

James Lanthier


A seasoned technology executive with strong expertise in corporate finance, public markets and M&A.

Most recently, Mr. Lanthier was a co-founder and CEO of Future Fertility, an innovative early stage developer of AI applications for human infertility.

As a C-Suite executive, Mr. Lanthier has assisted in the growth and successful exit of numerous technology-enabled businesses through the public markets, including Mood Media, the world’s largest in-store media provider, and Fun Technologies, a pioneer in online casual games.

Arvin Ramos


Mr. Ramos holds a degree in commerce and a member of the Chartered Professional Accountants of Ontario.

Mr. Ramos has over 15 years of business experience, having supported a broad range of industries, including mining, technology and banking.

Mr. Ramos serves as CFO of several junior mining companies.

Joseph Araujo


A behavioural pharmacologist with extensive experience in facilitating the discovery and development of novel CNS drugs.

He has co-founded, held executive level positions and consulted for Life Science  companies including CanCog Technologies, Vivocore, Karyopharm Therapeutics, NPM Pharma, Ketogen, and Epione Animal Health.

He did his graduate training in pharmacology at the  University of Toronto and has done extensive research examining psychoactive drugs.

Malik Slassi, Ph.D.

Senior VP of Innovation

Dr. Slassi was the Founder, President and Chief Scientific Officer of Fluorinov Pharma Inc. acquired by Trillium Therapeutics (NASDQ: TRIL) in January 2016. He is a medicinal chemist with a remarkable track record of success in drug discovery & development in the biopharmaceutical industry, spanning a period of over 30 years.

He has significant experience in the successful identification and development of drug candidates across multiple therapeutic areas including Neurology, Psychiatry and Immunology. Dr. Slassi has extensive experience in the areas of intellectual property management, corporate and scientific operations.

He is an accomplished inventor with over 130 issued and published patents and patent applications, and author of more than 65 scientific and review articles. Dr.Slassi holds a Ph.D. in chemistry from the University of Claude Bernard, Lyon, France and completed his postdoctoral training at the Chemistry Department of the University of Montreal, Canada.

Jason Atkinson

Corporate Development

A finance professional with experience in private equity, venture capital, investment banking and corporate finance.

He has played a key role in raising capital and providing advisory services to private and publicly listed entities across multiple industries.

He holds an MBA from the Degroote School of Business and is a CFA Charterholder. 

Richard Patricio


President and CEO of Mega Uranium Ltd., a uranium-focused investment and development company with assets in Canada and  Australia.

He is a qualified lawyer (Ontario) with over 15years of experience working with and for public companies.

He  has built a number of mining companies with global operations and spent 10 years with a TSX-listed investment company focused in the early-stage investment space. Mr.Patricio holds and has held senior officer and director positions in several companies that are listed on the TSX, ASX, NYSE and AIMexchanges.

Mr. Patricio received his law degree from  Osgoode Hall and was called to the Ontario bar in 2000. 

Philip Williams


More than 20 years of finance industry experience. His diverse experience includes roles as C-Suite Executive, as a sell-side research analyst, in fund management, managing director of investment banking and sits on the Board of several public companies in Canada.

James Passin


A 19-year hedge fund and private equity fund veteran with a deep experience in emerging market equities and venture  capital.

James is a director of BDSec JSC, the largest investment bank in Mongolia, where he was awarded the Friendship Medal by the Mongolian state.

Formerly a Principal at New York-based Firebird Management LLC, James has been called a “Daredevil  Investor” by the New York Times and “the Indiana Jones of Frontier Stock Markets” by the Financial Times.

Ian Dean

Director, Preclinical

Ian is a 30-year veteran of the non-clinical contract research industry across UK, Canada, Asia and the US.

In addition, Ian has spent 15 years as an independent regulatory consultant and is an expert external reviewer of the non-clinical section of new drug submissions for Health Canada.

Ian has extensive preclinical and clinical expertise spanning protocol design, report review, regulatory gap analysis, audit of non-clinical and clinical bioanalysis facilities, and preparing regulator documentation.

He is a Diplomate of the Institute of Biology in Toxicology(DIBT) and a Diplomate of the American Board of Toxicology (DABT; 1995-2015). 

Ali Kandil, Ph.D.

CMC Consultant

Ali Kandil, Ph.D., is a CMC consultant at Mindset Pharma who has 30+ years of experience in the pharmaceutical industry.

Dr. Kandil is an organic chemist and his experience spans vaccine development, biopharmaceuticals, API (intermediates), finished dosage form, CMOs manufacture support in both process development and manufacturing setting.

Dr. Kandil possesses a deep understanding of business strategy, lean manufacturing in biopharmaceutical environment relating to product development, manufacturing, technology transfer, clinical supply, quality assurance, quality control, CMC submissions, serialization and product launch.

In addition, he has provided expert technical support for the timely resolution of complicated CMC technical issues raised by FDA application reviewers.

Dr. Kandil started his career as a research chemist at SynPhar Laboratories, then moved to Sanofi Pasteur where he worked on vaccine development and then progressed to managerial career with increasing responsibilities in vaccine development and operations.

In 2003, he joined NPS Pharmaceuticals as director of manufacturing, then promoted to senior director then head of manufacturing and supply chain overseeing product development, manufacturing, and launch of two biopharmaceuticals products in the US and Europe until Shire acquired NPS Pharmaceuticals in 2015.

Dr. Kandil received a Ph.D. from Simon Fraser University, Canada, a Master’s in organic chemistry from Ain, Egypt, and he is a certified PMP.

Dr. Kandil has published many publications in peered review journals and hold multiple patents in vaccine and adjuvant development. 

Guy Higgins, Ph.D.

Scientific Advisor

Dr. Higgins has over 20 years of International CNS Research and Development experience with major BioPharma organizations such as Glaxo-Wellcome, Hoffmann-La Roche, Schering Plough and NPS Pharmaceuticals.

He has supported the identification and progression of novel chemical entities from early discovery through to clinical development (> 10 entering IND phase, 3 to market).

Dr. Higgins has significant experience in serotonin research, both in terms of contributions to drug discovery programs and applied research.

He has co-authored over 150 research papers and review articles covering aspects of CNS pharmacology, drug discovery and behavioural neuroscience.

Additionally, he has over 70 publications in serotonin-based research. He received PhD in 1990 and currently holds the position of Adjunct Professor in the Pharmacology department at the University of Toronto.

He currently serves as the Chief Scientific officer at InterVivo Solutions. 

Ishrat Husain, M.D.

Scientific Advisor

Dr. Ishrat Husain is at the forefront of research into the neurobiology of depression and bipolar disorder, and currently conducting clinical trials of emerging treatments for these conditions.

Dr. Husain has published over 40 research papers investigating the neurobiology and associated clinical care of mood disorders.

He is currently the Lead of the Mood Disorders Service and Clinician Scientist in the General Adult Psychiatry and Health Systems Division at the Centre for Addiction and Mental Health (CAMH), as well as an Assistant Professor in the Department of Psychiatry at the University of Toronto.

Prior to Dr. Husain’s work at CAMH, he was an academic psychiatrist in the UK.

Dr. Husain earned his Bachelor of Medicine and Bachelor of Surgery from St. George’s University of London and received his Doctorate of Medicine Research from the world renowned Institute of Psychiatry, Psychology and Neuroscience at King’s College London.

His current research focuses on clinical trials of novel treatments that target established pathology in mood disorders. 

Joseph Gabriele, Ph.D.

Scientific Advisor

Dr. Gabriele is a molecular pharmacologist specializing in signal transduction within the central nervous system.

He is the co-founder of Delivra Corp, a transdermal delivery platform that can shuttle small biologics to large peptides across the skin layers in a targeted, specific manner.

He has received numerous awards throughout his career, including a Canadian Institutes of Health Research (CIHR) studentship award in pharmacology, a Natural Sciences and Engineering Research Council of Canada (NSERC) Graduate Scholarship, and an Ontario Mental Health Foundation Postdoctoral Fellowship.

In 2007, he received the International Congress on Schizophrenia Research “New Investigator Award” and in 2008, the Hamilton Health Sciences “New Investigator Award” In 2018, Dr. Gabriele was the recipient of the Ernst & Young Entrepreneur of the Year in the health care category.

He received his B.Sc degree from the University of Toronto and completed his M.Sc. and Ph.D. degrees at McMaster University. 

Michael Rogawski M.D., Ph.D.

Scientific Advisor

Dr. Rogawski is a professor of neurology and pharmacology at the University of California Davis and is an internationally recognized expert on drug discovery and development for epilepsy.

Dr. Rogawski has received the NIH Director’s Award; the Epilepsy Research Award for Outstanding Contributions to the Pharmacology of Antiepileptic Drugs from the American Society for Pharmacology and Experimental Therapeutics; and the American Academy of Neurology Neuroendocrine Research Award.

He is an elected fellow of the American Association for the Advancement of Science, and in 2019 received the UC Davis Chancellor’s Innovator of the Year Award. Dr.Rogawski graduated from Amherst College with a B.A. in biophysics and from Yale University with an M.D. and Ph.D. in pharmacology.

He completed postdoctoral training in the Laboratory of Neurophysiology at the National Institute of Neurological Disorders and Stroke and residency training in neurology at Johns Hopkins.

Until 2006, he was a senior investigator and chief of the Epilepsy Research Section at NINDS and subsequently was appointed chair of the Department of Neurology at UC Davis.

He has served on the board of directors of the American Epilepsy Society and as an advisor to the NIH and the U.S. Food and Drug Administration. He is past president of the American Society for Experimental Neurotherapeutics.

Subscribe for latest news